DVAX - Dynavax Technologies Corporation
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
EmeryVille,
United States
Type: Equity
DVAX price evolution
DVAX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $112.5 | $132.03 | $150.28 | |
| Short term investments | $623.11 | $591.5 | $592.02 | |
| Net receivables | $75.28 | $62.63 | $46.15 | $44.53 |
| Inventory | $62.4 | $62.46 | $61.81 | $53.29 |
| Total current assets | $926.24 | $882.01 | $851.29 | $859.12 |
| Long term investments | ||||
| Property, plant & equipment | $59.2 | $58.63 | $59.8 | $61.58 |
| Goodwill & intangible assets | $2.01 | $2.02 | $2.07 | |
| Total noncurrent assets | $134.31 | $135.28 | $137.98 | |
| Total investments | $623.11 | $591.5 | $592.02 | |
| Total assets | $1061.99 | $1016.32 | $986.57 | $997.1 |
| Current liabilities | ||||
| Accounts payable | $7.09 | $4.55 | $2.43 | $5.25 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $70.03 | $62.19 | $56 | $62.2 |
| Long term debt | $223.56 | $250.75 | $251.54 | $252.42 |
| Total noncurrent liabilities | $311.28 | $312.08 | $312.83 | |
| Total debt | $250.75 | $251.54 | $252.42 | |
| Total liabilities | $380.56 | $373.47 | $368.08 | $375.02 |
| Shareholders' equity | ||||
| Retained earnings | -$910.33 | -$927.92 | -$939.3 | -$930.58 |
| Other shareholder equity | $0.51 | -$4.91 | -$4.37 | -$2.11 |
| Total shareholder equity | $642.85 | $618.48 | $622.07 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $150.28 | $202.21 | $436.41 | $32.31 |
| Short term investments | $592.02 | $422.39 | $109.76 | $132.96 |
| Net receivables | $44.53 | $147.51 | $131.82 | $22.66 |
| Inventory | $53.29 | $59.45 | $61.34 | $63.69 |
| Total current assets | $859.12 | $916.99 | $972.52 | $290.01 |
| Long term investments | ||||
| Property, plant & equipment | $61.58 | $63.34 | $60.98 | $57.15 |
| Goodwill & intangible assets | $2.07 | $2.01 | $2.13 | $2.3 |
| Total noncurrent assets | $137.98 | $68.86 | $66.73 | $63.26 |
| Total investments | $592.02 | $422.39 | $109.76 | $132.96 |
| Total assets | $997.1 | $985.85 | $1039.25 | $353.27 |
| Current liabilities | ||||
| Accounts payable | $5.25 | $3.21 | $2.6 | $3.31 |
| Deferred revenue | $349.86 | $38.21 | ||
| Short long term debt | ||||
| Total current liabilities | $62.2 | $150.07 | $556.4 | $77.41 |
| Long term debt | $252.42 | $221.58 | $254.81 | $214.6 |
| Total noncurrent liabilities | $312.83 | $254.76 | $260.47 | $217.17 |
| Total debt | $252.42 | $254.38 | $254.81 | $214.6 |
| Total liabilities | $375.02 | $404.84 | $816.87 | $294.58 |
| Shareholders' equity | ||||
| Retained earnings | -$930.58 | -$924.2 | -$1217.35 | -$1294.06 |
| Other shareholder equity | -$2.11 | -$5.44 | -$2.27 | $0.27 |
| Total shareholder equity | $622.07 | $581.01 | $222.37 | $58.69 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $73.8 | $50.79 | $55.6 | |
| Cost of revenue | $11.98 | $10.97 | $8.69 | |
| Gross Profit | $61.81 | $39.82 | $46.91 | |
| Operating activities | ||||
| Research & development | $14.95 | $13.53 | $14.12 | |
| Selling, general & administrative | $41.66 | $44.06 | $41.28 | |
| Total operating expenses | $56.61 | $57.59 | $55.4 | |
| Operating income | $5.2 | -$17.77 | -$8.49 | |
| Income from continuing operations | ||||
| EBIT | $16.6 | -$9.8 | $2.69 | |
| Income tax expense | $3.52 | -$2.78 | $0.78 | |
| Interest expense | $1.7 | $1.7 | $1.69 | |
| Net income | ||||
| Net income | $11.39 | -$8.72 | $0.22 | |
| Income (for common shares) | $11.39 | -$8.72 | $0.22 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $232.28 | $722.68 | $439.44 | $46.55 |
| Cost of revenue | $50.17 | $262.15 | $173.57 | $13.91 |
| Gross Profit | $182.12 | $460.53 | $265.87 | $32.64 |
| Operating activities | ||||
| Research & development | $54.89 | $46.6 | $32.23 | $28.61 |
| Selling, general & administrative | $152.95 | $131.41 | $100.16 | $79.26 |
| Total operating expenses | $219.15 | $177.01 | $131.38 | $101.01 |
| Operating income | -$37.03 | $283.52 | $134.49 | -$68.37 |
| Income from continuing operations | ||||
| EBIT | $2.39 | $301.03 | $88.7 | -$56.18 |
| Income tax expense | $2.02 | $1.14 | $0.81 | |
| Interest expense | $6.76 | $6.73 | $11.18 | $19.06 |
| Net income | ||||
| Net income | -$6.39 | $293.16 | $76.71 | -$75.24 |
| Income (for common shares) | -$6.39 | $292.87 | $72.14 | -$75.24 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $11.39 | -$8.72 | $0.22 | |
| Operating activities | ||||
| Depreciation | $1.98 | $1.95 | $1.96 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $13.52 | $13.01 | $11.31 | |
| Total cash flows from operations | $10.71 | -$16.68 | $13.77 | |
| Investing activities | ||||
| Capital expenditures | -$0.78 | -$0.75 | -$1.72 | |
| Investments | -$27.99 | $3.58 | -$18.52 | |
| Total cash flows from investing | -$41.4 | -$28.77 | $2.83 | -$20.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.42 | $2.54 | $2.02 | |
| Net borrowings | ||||
| Total cash flows from financing | -$3.14 | -$1.42 | -$4.2 | $1.78 |
| Effect of exchange rate | $0.1 | -$0.06 | -$0.2 | $0.48 |
| Change in cash and equivalents | -$30.94 | -$19.53 | -$18.25 | -$4.22 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$6.39 | $293.16 | $76.71 | -$75.24 |
| Operating activities | ||||
| Depreciation | $7.28 | $6.67 | $7.01 | $6.83 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $42.59 | $32.91 | $21.29 | $13.48 |
| Total cash flows from operations | $100.56 | $62.72 | $335.53 | -$92.25 |
| Investing activities | ||||
| Capital expenditures | -$3.1 | -$6.14 | -$8.48 | $2.78 |
| Investments | -$150.82 | -$309.86 | $22.7 | -$22.31 |
| Total cash flows from investing | -$153.93 | -$316 | $14.22 | -$26.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.89 | $11.07 | $35.57 | $109.5 |
| Net borrowings | $29.63 | |||
| Total cash flows from financing | $1.39 | $19.52 | $55.78 | $109.5 |
| Effect of exchange rate | $0.32 | -$0.44 | -$1.43 | $1.49 |
| Change in cash and equivalents | -$51.66 | -$234.2 | $404.1 | -$7.79 |
News
Fundamentals
| Market cap | $1.47B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 131.34M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.60 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 13.23 |
| Quick ratio | 12.34 |